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Abstract
Background. Worsening of Chronic Obstructive Pulmonary Disease (COPD) may decrease the quality of 
life of patients. Rehabilitation of patients with COPD may increase exercise tolerance and improve quality of 
life. Pursed-Lips Breathing (PLB) activates abdominal muscles during expiration for improving gas exchange 
and oxygen saturation in the arteries, increasing the tidal volume and reduce shortness of breath, anxiety 
and tension thus improving the quality of life. St George's Respiratory Questionnaire (SGRQ) was a tool 
to measure the quality of life of patients with COPD, which has been validated. Patients with improved 
quality of life were characterized by a decrease in SGRQ score after PLB training.
Aims. Analyze the eff ect of improved quality of life in patients with stable COPD using PLB + standard 
therapy compared to standard therapy only.
Methods. Th is research used an open-label Randomized Controlled Trial (RCT) design and conducted in 
patients ith COPD stage 2 and 3. It was performed in Rumah Sakit Khusus Paru (RSKP) Respira Bantul, 
Yogyakarta. Th e study group was composed of 47 subjects, who continued the previous standard therapy 
and performed PLB 8 minutes once a day for 28 days. Th e placebo group (44 samples) continued the 
previous standard therapy alone. Measuring the quality of life using the SGRQ performed in both groups 
before and after the experiment. Statistical analysis included independent t-test and Mann Whitney U-test. 
Results. Th ere were improvements in the quality of life that clinically characterized by a decrease in SGRQ 
total score of 12.19 points out of 100 points total in the PLB group. Th ere was a very signifi cant diff erence 
in the decline in total SGRQ score between the study group and placebo groups (p <0.001).
Conclusion. Pursed-Lips Breathing (PLB) improve the quality of life of patients with stable COPD was 
characterized by a decrease in SGRQ of 12.19 points out of 100 points total.
Keywords.  COPD (Chronic Obstructive Pulmonary Disease),  PLB (Pursed-Lips Breathing),  SGRQ (St George’s 
Respiratory Questionnaire),  quality of life
Abstrak
Latar Belakang. Pemberatan PPOK menyebabkan penurunan kualitas hidup pada penderita. Rehabilitasi 
penderita PPOK dapat meningkatkan toleransi latihan dan meningkatkan kualitas hidup. Pursed-Lips Breathing 
(PLB) mengaktifkan otot perut selama ekspirasi sehingga meningkatkan pertukaran gas dan saturasi oksigen di 
arteri, meningkatkan volume tidal dan mengurangi sesak nafas, rasa cemas dan tegang karena sesak sehingga 
memperbaiki kualitas hidup. St George’s Respiratory Questionnaire (SGRQ) adalah alat untuk mengukur kualitas 
hidup pasien PPOK yang telah divalidasi. Pasien dengan perbaikan kualitas hidup ditandai dengan terjadinya 
penurunan skor SGRQ sesudah latihan PLB.
Tujuan Penelitian. Menganalisis pengaruh perbaikan kualitas hidup pada penderita PPOK stabil dengan 
menggunakan terapi standar + PLB dibanding hanya terapi standar.
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Introduction 
Chronic Obstructive Pulmonary Disease 
(COPD) is a health problem in the world 
by the number of year-to-year increased 
and causes a decrease in the quality of life 
in patients.1 Rehabilitation in patients with 
COPD may increase exercise tolerance and 
improve quality of life. Pursed-Lips Breathing 
(PLB) activated abdominal muscles during 
expiration thus improving gas exchange and 
oxygen saturation in the arteries, increasing the 
tidal volume and reduces shortness of breath, 
anxiety, and tension because of tightness that 
improves the quality of life.2 
St George's Respiratory Questionnaire 
(SGRQ) was a tool to measure the quality of 
life of patients with COPD that have been 
validated.3 Patients with improved quality of 
life were characterized by a decrease in SGRQ 
score after practice PLB.
Th is study aimed to analyze the eff ect 
of improved quality of life in patients with 
stable COPD using PLB plus standard therapy 
compared to standard therapy only.
Method
Th is research used experimental research 
design, an open-label randomized controlled 
trial (RCT). Data as collected at the Respira 
Bantul Lung Hospital (RSKP) from 1 August 
2016 - 7 January 2017. Th e treatment group 
(PLB) was composed of 47 samples, continuing 
the previous standard therapy and perform 
PLB 8 minutes once a day for 28 days (4 
weeks) in a row. Th e placeo group (44 samples) 
continues the previous standard theraphy. 
Approval from the Ethics Committee 
was received. Informed consent as obtained 
from all research subjects. Subjects who met 
the inclusion criteria randomly assigned as 
PLB or controls. 
Th e inclusion criteria were COPD patients 
stable with GOLD 2 or 3 degrees. Th e subject 
had received routine therapy for at least 3 
months, not suff ering from illness, malignancy, 
diabetic retinopathy, ischemic heart disease, 
chronic kidney disease (LFG <15), rheumatoid 
arthritis, systemic sclerosis, lupus erythematosus, 
polymyositis or dermatomyositis, osteoporosis, 
vertebral compression fractures, scoliosis, chronic 
Metode. Penelitian ini menggunakan desain penelitian eksperimental, Randomized Controlled Trial (RCT), open 
label. Penelitian dilakukan pada pasien PPOK stadium 2 dan 3 di Rumah Sakit Khusus Paru (RSKP) Respira 
Bantul, Yogyakarta. Kelompok perlakuan (PLB) terdiri dari 47 sampel, meneruskan terapi standar sebelumnya dan 
melakukan PLB 8 menit sehari sekali selama 28 hari berturut-turut. Kelompok plasebo (44 sampel) meneruskan 
terapi standar sebelumnya saja. Pengukuran kualitas hidup menggunakan SGRQ dilakukan pada kedua kelompok 
baik sebelum maupun sesudah perlakuan. Pengaruh latihan PLB terhadap perbaikan hidup menggunakan SGRQ 
pada kelompok perlakuan dibanding plasebo diuji dengan independent t-test/mann whitney u-test.
Hasil Penelitian. Terdapat perbaikan kualitas hidup secara klinis ditandai dengan penurunan skor total SGRQ 
sebesar 12,19 poin dari 100 poin total pada kelompok PLB. Terdapat perbedaan sangat bermakna terhadap 
penurunan nilai total SGRQ antara kelompok perlakuan dan kelompok plasebo setelah mendapat perlakuan (p 
<0,001).
Kesimpulan. Pursed-Lips Breathing (PLB) memperbaiki kualitas hidup penderita PPOK stabil ditandai dengan 
penurunan SGRQ sebesar 12,19 poin dari 100 poin total.
Kata kunci: COPD (Chronic Obstructive Pulmonary Disease), PLB (Pursed-Lips reathing, SGRQ (St George's 
Respiratory Questionnaire), kualitas hidup
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the improvement of life using the SGRQ in 
the treatment group was compared to placebo 
using independent t-test/Mann Whitney U-test. 
The St George's Respiratory Questionnaire 
(SGRQ) was a tool to measure the quality of 
life of patients who have COPD validated. Th e 
questionnaire contained 76 questions and 3 
components of the score, to assess the severity of 
symptoms, limited activity, social and emotional 
impact. Th e higher the SGRQ score showed the 
lower the quality of life.3
Th e reason for using SGRQ because it 
validated to measure impaired health quality 
in patients with COPD and asthma. The 
use of SGRQ in COPD patients with an 
-coeffi  cient of 0.76-0.77, so that the used 
of SGRQ as an indicator of the quality of life 
was very specifi c.5 SGRQ consists of two parts, 
the fi rst part showed the symptom score and 
the second part showed the activity score and 
disease impact score.6
Br i t i sh  Thorac ic  Soc ie ty  (BTS) 
recommend used SGRQ because it was more 
sensitive to assess clinical changes. Th e SGRQ 
questionnaire can be used to detect responses 
to medical or non-medical procedures such as 
pulmonary rehabilitation programs. Clinical 
changes were minimally significant if the 
SGRQ value decreased by 4%. SGRQ value 
in this study exceeded the minimally clinically 
signifi cant change (21%).
The adjusted SGRQ questionnaire can 
objectively assess the eff ects of the disease on 
daily life. Assessment of quality of life proposed 
by PW Jones is the infl uence of disease on daily 
life. Th e SGRQ questionnaire more related to 
the quality of life than pulmonary physiological 
values. People with COPD due to progressive 
illness often experience psychological and 
social disorders. Th e disorder is in the form of 
depression, anxiety, anxiety, anger, threatened 
pain, osteoarthritis, quadriceps muscle weakness 
and gastroesophageal refl ux disease (GERD). 
Comorbidities were reviewed from the patient's 
medical record. Exclusion criteria included 
experienced acute exacerbations at the time of 
the study period and did not meet the minimum 
compliance requirements for running the PLB. 
The research flow can be seen in Figure 1. 
Power and Sample Size Calculation® Version 
3.0 Software calculated minimum sample size 
calculations for paired numerical analytical 
studies analyzing mean diff erences in clinical 
trials. 
Planned studies from independent controls 
and experimental subjects with 1 control per 
experimental subject. In a previous study by 
Alma HJ et al4, the response in each group of 
subjects normally distributed with a standard 
deviation of 18.6. If the true diff erence in the 
experimental and control facilities is 12.87, 
then a sample of 45 experimental subjects and 
45 control subjects were needed to be able to 
reject the null hypothesis that the population 
means the experimental and control groups 
are equal to probability (power) 0.9. Th e error 
type I probability associated with this test from 
this null hypothesis is 0.05. It is estimated that 
drop out in this study is 20% so the sample size 
is 55 subjects per research group. Th e treatment 
group continued with standard therapy, gave 
pursed-lip breathing technique training every 
day for 4 weeks, and then evaluated the quality 
of life with a questionnaire. Th e control group 
divided into 2 stages. Stage I followed standard 
therapy without performing PLB tehnique 
training then were evaluated the quality of life 
with a questionnaire. Th e patient was given a 
pursed-lip breathing technique in the second 4 
weeks as a placebo in stage II. Measurement of 
the quality of life using the SGRQ performed 
in both groups before and after treatment. 
Purse-Lips Breathing exercise influence on 
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death, fatigue, and others. Th e prevalence of 
depression in COPD patients estimated at 42%. 
Other symptoms of depression such as feeling 
sad, no motivation, feeling tired or not powerful, 
suicidal desires and psychomotor setbacks often 
occur in patients with COPD. Other factors 
that cause depression include disruption of daily 
activities, unable to work like peers because of 
the progressive disease. The adjusted SGRQ 
questionnaire can objectively assess the eff ect of 
the disease on daily life. Assessment of quality 
of life proposed by PW Jones is the infl uence of 
disease on daily life. Th e SGRQ questionnaire 
more related to the quality of life than pulmonary 
physiological values.
Results
Result Data were collected at the Respira 
Lung Hospital (RSKP) Bantul from 1 August 
2016 - 7 January 2017. Patients who controlled 
to the Polyclinic Respira Lung Hospital Bantul 
after being examined by Lung specialists and 
fulfi lling the inclusion criteria were subjected to 
the study and informed consent was conducted 
followed by randomization. Th e research fl ow 
can be seen in Figure 1.
Pursed-Lips Breathing group consisted of 
30 men (69.2%) and 17 women (30.8%), while 
the placebo group consisted of 31 men (67.6%) 
and 13 women (32.4%). Th e mean age of PLB 
group was 63.32 ± 7.11 and the placebo group 
was 64.82 ± 8.28 years. Pursed-lips Breathing 
group mean body weight 53.15 ± 10.40 kg and 
placebo group 53.75 ± 1.54kg.
Th e average height was 1.59 ± 0.07 PLB 
group and the placebo group was 1.59 m ± 0.06 
m, while the mean body mass index (BMI) PLB 
group 20.90 ± 3.51 kg/m2 and IMT placebo 
group 21.14 ± 3.77 kg/m2. Smoking status in the 
group PLB showed 15 subjects of nonsmokers, 
24 subjects of ex-smokers, passive smokers do not 
exist and 8 subjects of active smokers. Th e placebo 
group showed 14 subjects of nonsmokers, 23 
subjects of ex-smokers, 3 subject of passive 
smokers, and 4 subjects with active smokers. 
Routine therapy used in the PLB group, there 
were 13 subjects used only bronchodilators and 34 
subjects used bronchodilators + corticosteroids. 
In the placebo group, there were 12 subjects 
used only bronchodilators and 32 subjects used 
bronchodilators + corticosteroids. 
Spirometry performed on the PLB and 
placebo group both before and after treatment 
with the assessment of Forced Vital Capacity 
(FVC) and Expiration Force V. The basic 
characteristics of the study subjects were the 
infl uence of PLB for 4 weeks on COPD patients 
in the PLB group compared to the placebo group 
on quality of life which included sex, age, weight, 
height, body mass index (BMI) smoking status, 
routine therapy and spirometry results before 
treatment. Th e details were in fi gure 1.  
All characteristics of subjects in the 
PLB and the  placebo group were normally 
distributed when checked with Shapiro-Wilk 
test.  
The PLB group consisted of 30 men 
(69.2%) and 17 women (30.8%) while the 
placebo group consisted of 31 men (67.6%) 
and 13 women respectively (32.4%). The 
average age of the PLB group was 63.32 ± 7.11 
years and the placebo group 64.82 ± 8.28 years. 
Th e mean weight of the PLB group was 53.15 
± 10.40 kg and the placebo group was 53.75 
± 1.54 kg. Th e mean height of the PLB group 
was 1.59 ± 0.07 m and the placebo group was 
1.59 ± 0.06 m, while the mean body mass index 
(BMI) of the PLB group was 20.90 ± 3.51 kg/
m2 and the placebo group BMI was 21.14 ± 
3.77 kg/m2. Smoking status in the PLB group 
showed nonsmokers 15 subjects, ex-smokers 
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24 subjects, no passive smoking, 8 active 
smokers, and in the placebo group, there were 
14 smokers, 23 smokers, 3 passive smokers, 
active smokers 4 subjects. Routine therapy 
used in the PLB group consisted of 13 subjects 
using bronchodilators alone and 34 people 
using bronchodilators and corticosteroids. In 
the placebo group, there were 12 people using 
bronchodilators alone and 32 people using 
bronchodilator + corticosteroids.
Spirometry performed in the PLB group 
and placebo both before and after therapy with 
the Forced Vital Capacity (FVC), Volume 1 
Force Expiration (FEV1), FEV1 / FVC and 
FEV1 / Prediction. Predicted FEV1 values 
taken from values according to the standards 
in Indonesia. After calculation, there was 
no significant difference in the value of 
spirometry between the PLB group and the 
placebo group. For the basic characteristics of 
post-experimental spirometry, results showed 
in table 2 below, equipped with delta values 
between pre and post research experiments. 
Table 3 displayed data of SGRQ score 
based on symptom, activity and impact. Total 
scores were compared before and after theraphy. 
Tested by Shapiro-Wilk, PLB group activity 
score after therapy as normally distributed.  Th e 
data was not normally found in the placebo 
group for activity score before and after therapy. 
Th ere as no diff erence between before and after 
treatment on symptom scores, activity score, and 
total impact score. While in the PLB group, there 
were signifi cant diff erences in all scores. In table 
4, there was no signifi cant diff erence between 
dleta of statistical and clinical symptoms between 
the PLB group and the placebo group. Th is can 
be seen from the delta symptom score change in 
the PLB group which was 9.99+1.91 compared 
to the standard group of symptoms delta score 
of 7.25+1.37 (p = 0.138)using unpaired t-test. 
Incontrary, there were significant differences 
Figure 1. Research fl ow
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Table 1. Characteristic of subject
Variable
PLB group (n=47) Placebo group (n=44)
x/t/u p-value
n (%) or Mean ± SD
Sex        
Male 30 (69.2%) 31 (67.6%) 0.451 0.502*
Age (years old) 63.32±7.11 64.82±8.28 2.481 0.119**
Weight (kg) 53.15±10.40 53.75±1.54 0.011 0.916**
Height (m) 1.59±0.07 1.59±0.06 2.478 0.119**
Body Mass Index (kg/m2) 20.90±3.51 21.14±3.77 0.200 0.655**
Smoking status        
None, n (%) 15 14 4.295 0.231*
History, n (%) 24 23    
Passive smoker, n (%) 0 3    
Active smoker, n (%) 8 4    
Th erapy        
None 0 0 0.002 0,577*
Bronchodilator 13 12    
Corticosteroid 0 0    
Bronchodilator+Steroid 34 32    
Pre        
FEV1 (liter) 1.03±0.37 1.02±0.39 0.154 0.696**
FVC (liter) 1.75±0.80 1.54±0.44 3.295 0.073**
FEV1/FVC (%) 60.84±1.31 65.80±1.33 0.228 0.634**
FEV1/FEV Predicted (%) 54.00±1.32 53.84±1.43 1.297 0.258**
p-value <0.05 signifi cantly diff erence, *Chi-square test, **independent T-test
Table 2. Basic characteristic spirometry value of post and delta intervention
Variable
PLB group (n=47) Placebo group (n=44)
x/t/u p-value
n (%) or Mean ± SD
Post        
FEV1 (liter) 1.10±0.42 1.02±0.96 0.321 0.572**
FVC (liter) 1.66±0.55 1.54±0.43 3.413 0.068**
FEV1/FVC (%) 66.81±1.32 65.89±1.24 1.018 0.060**
FEV1/FEV predicted (%) 57.89±1.58 0.444 0.507**
Delta        
FEV1 (liter) 0.08±0.18 -0.01±0.09 2.784 0.099**
FVC (liter) -0.03±0.09 -0.01±0.07 0.154 0.696**
FEV1/FVC (%) 5.43±8.78 0.24±4.93 2.434 0.123**
FEV1/FEV predicted (%) 4.42±8.78 -0.37±4.90 3.434 0.068**
*p-value <0.05 signifi cantly diff erence, *Chi square test, **independent t test
between the groups in term of delta of activity, 
impact, and total score. 
Th ere were no normal distribution of 
data on each of the delta, Mann-Whitney-U 
test was then used showing the delta of activity 
(p= <0.001), delta of impact (p= 0.001) and 
the delta of total (p= <0.001).
Discussion
Pulmonary exercise rehabilitation using 
PBL has eff ect on oxygen increase. It increases 
tidal volume and decreases respiratory rate 
so that the respiratory muscles work more 
effectively and decrease the workload of 
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breathing. Th is does not waste much energy 
and patient does not easily get tired. The 
procedure can be performed as daily activity 
and may increase the quality of life.7
The severity of COPD in this study 
based on Gold II and III. A systemic review 
conducted by Tsiliglanni et al8, observed a 
signifi cant relationship between the severity 
of COPD and quality of life. The severity 
of COPD caused by airway obstruction will 
aff ect the quality of life of patients with COPD 
without seeing how long he had been suff ering 
from COPD.9 Stage IV COPD stage marks the 
threshold fi nally deteriorating health status in 
parallel with decreased lung function which 
worsen the quality of life of patients.10
This study found the statistically 
significant difference in delta activity 
(p=<0.001), delta eff ect (p=0.001) and total 
delta (p=<0.001) between the PLB groups 
(n=47) compared to the placebo group (n=44), 
here the diff erence in the PLB group showed a 
Table 3. Diff erence of score SGRQ between PLB group and placebo group 
Variable
PLB group Placebo group t/u test p-value
(n=47) (n=44)   (IK 95%)
SGRQ value
Symptom score
Pre therapy
Mean ± SD 50.61 ± 2.00 46.63 ±2.05 0.073 0.788*
Median 58.60 46.99
Post-therapy
Mean ± SD 40.62 ± 2.09*** 39.38 ± 2.14# 0.490 0.486*
Median 40.89 39.40
Activity score
Pre therapy
Mean ± SD 38.10 ± 2.47 25.52 (0.00-67.29) -2.600 0.009**
Median 35.62 17.81
Post-therapy
Mean±(Min-Max) 24.25 (0.00-93.37) ***$ 26.77 (0.00-63.42) # -1.069 0.285**
Median 18.08 23.33
Impact score 
Pre therapy
Mean ± SD 38.01 ± 1.45 27.06 ± 1.58 1.191 0.278*
Median 39.92 28.79
Post-therapy
Mean ± SD 26.07 ± 1.62*** 26.50 ± 1.58# 0.419 0.519*
Median 27.68 27.50
Total score
Pre therapy
Mean ± SD 39.99 ± 1.66 29.63 ± 1.49 0.177 0.675*
Median 41.13 30.10
Post-therapy
Mean ± SD 27.80 ± 1.63*** 28.59 ± 1.46# 0.212 0.646*
Median 28.85 28.00    
P-value <0.05 signifi cantly diff erence * Independent T-test between PLB group and placebo group, **Mann-Whitney test 
between PLB group and placebo group, ***Paired T-test/Wilcoxon test between pre and post-therapy in PLB group, #Paired 
T-test/Wilcoxon test between pre and post-therapy in placebo group, $signifi cantly diff erence (p=<0.001)
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a signifi cant decrease in scores. Th ere were no 
signifi cant diff erence in the occurrence of delta 
symptom score (p=0.138) between the groups 
can be explained because of the PLB and the 
placebo group. Th e decrease in symptom scores 
before and after treatment was signifi cantly 
diff erent. 
Roche et al11, observed similar result with 
our finding by seeing an improved quality 
of life based on PLB Airways Questionnaire 
20 (AQ20). AQ20 questionnaire has been 
deeloped to measure and calculate interference 
in daily activities and health-related quality 
of life (HRQOL) of patients with asthma or 
COPD. Other results were also similar to the 
present study showing the increase spirometry 
values of FEV1 (%) of 56.9 ± 9.4 be 57.9 ± 
10.4 after the intervention. In the present study 
obtained FEV1 (%) 54.00 ± 1.32 PLB group 
became 57.89 ± 1.58.
Ramos et al12, in  a cross- sectional study 
on 16 patients with COPD GOLD I, II and 
III state that the exercise PLB for 8 minutes 
improvements in vital signs that was expressed 
by decrease of breath frequency, increased 
oxygen saturation, and a decrease in the average 
pulse. However, no change in blood pressure 
was found.
To prevent bias against change in the 
quality of life for COPD patients with SGRQ, 
this research, exluded data with potential 
confounder. According to Jones13 the presence 
of comorbidity > 3 is associated with a worse 
quality of life compared with comorbides <3. 
Patients with cardiovascular disease had worse 
SGRQ score (45.8 ± 19.5) than those without 
(43.2 ± 19.2).
Conclusion
Pursed-Lips Breathing (PLB) improved 
the patients’ quality of life with stable COPD 
and characterized by the decrease of SGRQ 
score.
Table 4. Diff erence of delta SGRQ score before and after therapy between PLB group and 
placebo group
Variable
PLB group Placebo group
t/u test
p-value
(n=47) (n=44) IK 95%
DeltaSGRQ
Activity score
Mean ± SD 9.99 ± 1.91 7.25 ± 1.37 2.239 0.138*
Median 8.47 2.26
Activity score
Mean ± SD 13.86 ± 1.83 -1.25 (-60.81-35.63) -3.544 <0.001**
Median 11.18 0.00
Impact score 
Mean ± SD 11.95 ± 1.60 0,56 (-38.62-20.17) -3.218 0.001**
Median 11.71 1.3
Total score
Mean ± SD 12.19 ± 1.35 1.05 (-40.72-23.52) -3.856 <0.001***
Median 12.31 1.10    
p-value<0.05 signifi cantly diff erence
*Independent t-test between PLB group and the placebo group
** Mann-Whitney U test between PLB group and the placebo group
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